What changed
LISRAYA (brepocitinib), a TYK2 and JAK inhibitor, is now FDA-approved for the treatment of dermatomyositis in adult patients. The approval was announced August 28, 2026. All other indications remain investigational and subject to regulatory approval. LISRAYA carries a boxed warning; full safety information is available at lisrayahcp.com/pi.
Why it matters
LISRAYA (brepocitinib), a TYK2 and JAK inhibitor, is now FDA-approved for the treatment of dermatomyositis in adult patients. The approval was announced August 28, 2026. All other indications remain investigational and subject to regulatory approval. LISRAYA carries a boxed warning; full safety information is available at lisrayahcp.com/pi.
← Dashboard
Sep 04, 2026 10:03 AM ET